Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

SAN DIEGO, March 15, 2013 /PRNewswire/ -- Senomyx, Inc. (NASDAQ: SNMX), a company using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients for the food, beverage, and ingredient supply industries, today reported financial results for the fourth quarter and full year ended December 31, 2012. The Company ended 2012 with $41.8 million in cash and highly liquid investments.  

The Company announced today that it is initiating a new direct sales strategy intended to accelerate Senomyx's transformation into a profitable company by expanding its focus from discovery and development to commercialization.  Rather than relying solely on licensing collaborations for commercialization, Senomyx will sell certain of its flavor ingredients directly to flavor companies for re-sale to food and beverage companies, expanding the market and creating new opportunities to increase total usage of Senomyx's products. 

"Senomyx intends to leverage our proprietary taste discovery technologies to become a leading commercial provider of novel flavor ingredients to the flavor industry," stated Kent Snyder, Chief Executive Officer of the Company.  "The direct sales strategy complements our existing collaborations, which are based on exclusive or co-exclusive commercialization licenses with our partners, who pay royalties to Senomyx. 

"The new strategy is expected to allow Senomyx to have a greater role in the commercialization process and realize more value from our discoveries.  Having numerous flavor companies marketing our flavor ingredients is expected to enable deeper and broader penetration of the food and beverage industry.  Senomyx will focus on sales of our pure, also commonly referred to as 'neat', ingredients to flavor companies, who can then add
'/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  Brooklyn residents now have a new ... pain and injuries. Nunzio Saulle , M.D., a ... of his NJS Physical Medicine and Rehabilitation (PM&R) practice ... March 5, 2015. Health Plus Management, LLC is managing ... at 1178 Flatbush Avenue. This new PM&R practice will ...
(Date:3/4/2015)... /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") today ... research program with Emerald Logic, a leader ... Technology (FACET), Emerald Logic analyzed Resverlogix,s complete ... each of 798 patients who participated in ... SUSTAIN and ASSURE. The objective of this ...
(Date:3/4/2015)... Pa. , March 4, 2015 /PRNewswire/ ... services and technology provider, today announced that ... 10 countries convened at its annual European ... to discuss the use of ... challenges. BioClinica,s eClinical technologies include: the Microsoft ...
(Date:3/4/2015)... Lancée par l,Assistance ... en décembre 2011, l,étude collaborative française randomisée ... compare   l es microsphères en résine ... le carcinome hépatocellulaire avancé, a recruté plus de ...   ; les résultats sont attendus fin 2016. ...
Breaking Biology Technology:NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... ,II. Product Components ,III. Materials to be ... of DNA from Whole Blood ,V. Protocol for ... Quantification of Amplified Products ,VII. Purification of Amplified ... , Contact Information , , , , ...
... Using siRNA for gene silencing is a, ... for preparing siRNA, such as chemical synthesis, in vitro transcription, ... cassettes. Irrespective, of which method ... to choose the siRNA target site. The guidelines below for choosing, ...
... , , ... , , This Application Note describes ... total RNA and fragmented cRNA by using,the Agilent 2100 bioanalyzer. The Eukaryote ... 28S/18S ratio in the,total RNA as well as detection of possible degradation. ...
Cached Biology Technology:Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 2Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 3Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 4Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 5Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 6siRNA Design Guidelines 2siRNA Design Guidelines 3siRNA Design Guidelines 4siRNA Design Guidelines 5siRNA Design Guidelines 6siRNA Design Guidelines 7Advancing the quality control methodology,to assess isolated total RNA,and generated fragmented cRNA 2Advancing the quality control methodology,to assess isolated total RNA,and generated fragmented cRNA 3Advancing the quality control methodology,to assess isolated total RNA,and generated fragmented cRNA 4Advancing the quality control methodology,to assess isolated total RNA,and generated fragmented cRNA 5Advancing the quality control methodology,to assess isolated total RNA,and generated fragmented cRNA 6
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... WINSTON-SALEM, N.C. , Jan. 16, 2015  A man-made ... working memory and other mental capabilities in adults with ... a pilot study led by researchers at Wake Forest ... 60 adults diagnosed with amnesic mild cognitive impairment (MCI) ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... and Workgroup Scanners Recognized by ... the Leading Guide for Office ... Fujitsu Computer Products of,America, Inc., a market leader in ... scanners earned the "Editor,s Choice",designation in the Better Buys ...
... Bacteria save energy by producing proteins that moonlight, having ... the microbes from being killed. The moonlighting activity of ... resistant to a family of broad-spectrum antibiotics, according to ... journal Microbiology. "Glutamate racemase, or ...
... 2008The many recent reports documenting the therapeutic efficacy of ... disease may actually be describing non-specific therapeutic effects related ... response, according to a paper in the September 2008 ... Therapy , a peer-reviewed journal published by Mary Ann ...
Cached Biology News:Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide 2Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide 3Energy-saving bacteria resist antibiotics 2Previous claims of siRNA therapeutic effects called into question by report in human gene therapy 2
... Ambions MAXIscript In Vitro Transcription Kits ... 1 x 10 9 cpm/g. High ... in ribonuclease protection assays, in situ hybridization, ... be used for the synthesis of modest ...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
... 250 ul (125 precipitations). ... easy pellet location.Efficient precipitation ... inert, compatible with most ... protocol. Category: DNA/RNA Synthesis ...
... for monitoring Aldolase tests. 2 levels ... targeted manufacturing values at 4 ± ... IU/L. 30-day shelf life once ... Level 1: 3 x 3 ml; ...
Biology Products: